MPR Weekly Dose 206 — OTC Glucose Monitors; RSV Vaccine Approval Expanded; Juvenile Idiopathic Arthritis Tx; Emflaza Generic; New Primary Biliary Cholangitis Tx
Release Date: 06/14/2024
MPR Weekly Dose Podcast #235 — Rinvoq Approval Expanded; Wegovy Telehealth Link-Up; Epidermolysis Bullosa Wound Healing Tx; Imaavy Approved for gMG; Nasal Powder to Treat Migraines
MPR Weekly Dose
Rinvoq approved for giant cell arteritis; telehealth companies collaborate with Novo Nordisk for Wegovy access; epidermolysis bullosa wound healing treatment approved; Imaavy approved for gMG; New nasal powder approved for migraine treatment.
info_outline
MPR Weekly Dose Podcast #234 — Alert for Compounded Finasteride; Cytisinicline Improves Smoking Cessation; GERD Tx Shows Promise; ACIP Makes New Vaccine Recs
MPR Weekly Dose
The FDA issues alert regarding a compounded topical finasteride; plant-based alkaloid shows improvement for smoking cessations; potential new treatment option for GERD; and the CDC’s Advisory Committee on Immunization Practices make new recommendations.
info_outline
MPR Weekly Dose Podcast #233 — Pfizer ends development of weight loss drug; counterfeit Ozempic seized; daily pill demonstrates HbA1c reductions; mavacamten misses trial endpoint; smart belt to reduce fall injury
MPR Weekly Dose
Pfizer ends danuglipron clinical program for obesity; FDA warns about counterfeit Ozempic; daily pill shows promise in reducing HbA1c; mavacamten misses in nonobstructive HCM trial and the FDA clears smart belt device reduce fall injury.
info_outline
MPR Weekly Dose Podcast #232 — Uplizna gains new approval; Vanrafia approved for proteinuria in IgAN; schizophrenia ER Tx now available; Imcivree shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk
MPR Weekly Dose
Uplizna gains new indication; Vanrafia approved for proteinuria in IgAN; Erzofri now available for schizophrenia; setmelanotide shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk.
info_outline
MPR Weekly Dose Podcast #231 — Treatment for hyperphagia in Prader-Willi Syndrome; Qfitlia Approved; Chlamydia Vaccine and OTC Test; Semaglutide Improves Walking; Imfinzi Approved for MIBC
MPR Weekly Dose
New treatments for Prader-Willi Syndrome and hemophilia; FDA fast tracks a chlamydia vaccine candidate; over-the-counter test cleared for identifying chlamydia, gonorrhea and trichomoniasis; semaglutide improves walking ability in patients with peripheral artery disease; and Imfinzi combo therapy approved for MIBC.
info_outline
MPR Weekly Dose Podcast #230 — New Antibiotic for uUTIs; Treatment Approved for Advanced Neuroendocrine Tumors; New Rosacea Tx Option; Tremfya Gains Crohn Disease Indication; Dept. of HHS Cuts 10,000 Jobs
MPR Weekly Dose
New antibiotic has been approved for uncomplicated UTIs; Cabometyx approved for advanced neuroendocrine tumors; new rosacea treatment option; Tremfya gains Crohn disease indication; Department of HHS cuts 10,000 jobs.
info_outline
MPR Weekly Dose Podcast #229 — Flu Vaccine Recommendations; Patient Dies Following Gene Therapy; Chikungungya Vaccine; Zunveyl Available; REMS Removed for Tryvio
MPR Weekly Dose
Influenza vaccine recommendations made for upcoming season; a patient dies following Elevidys infusion; Chikungunya vaccine now available and recommended for those traveling to areas with an outbreak; novel Alzheimer disease treatment launches; risk evaluation and mitigation strategies removed for hypertension treatment.
info_outline
MPR Weekly Dose Podcast #228 — Xolair biosimilar approved; Furoscix indication expanded; Novel implant for rare eye disease; Lorundrostat trial data; Elevated benzene in acne treatments
MPR Weekly Dose
First Xolair biosimilar approved, Wearable furosemide loop diuretic gains expanded indication; Implant approved for macular telangiectasia; Novel treatment shows promise in hypertension; And testing reveals high benzene levels in over-the-counter acne treatments.
info_outline
MPR Weekly Dose Podcast #227 — Labeling Changes for Testosterone Products; Food Allergy Treatments Compared; FDA Approves Stroke Tx; COVID-19, Flu Vaccine Effectiveness for Recent Season; Neffy 1mg Approved
MPR Weekly Dose
Labeling changes for testosterone products; food allergy treatments compared; FDA approves stroke Tx; COVID-19, flu vaccine effectiveness for recent season; Neffy 1mg approved
info_outline
MPR Weekly Dose Podcast #226 — REMS Removed for Schizophrenia Tx; New Copper Intrauterine Device; Wegovy, Ozempic Supply Update; Lumbar Disc Disease Tx Fast Tracked; Tourette Syndrome Shows Promise
MPR Weekly Dose
REMS requirement removed for schizophrenia treatment; new copper intrauterine device approved; Wegovy, Ozempic no longer in short supply; stem cell therapy for chronic lumbar disc disease fast tracked; ecopipam shows promise for Tourette syndrome.
info_outlineTwo glucose monitoring systems have been cleared for over-the-counter sale; Arexvy gains approval for adults aged 50 to 59 years; Kevzara approved for active polyarticular juvenile idiopathic arthritis; Generic Duchenne muscular dystrophy drug is made available; and Iqirvo gets accelerated approval for primary biliary cholangitis.